High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer.
Ontology highlight
ABSTRACT: Background: Emerging evidence suggests that delta-like ligand 4 (DLL4) and other members of the Notch pathway may offer new targets for development of anti-angiogenesis drugs for the treatment of several tumor types. However, the role of DLL4 in gastric cancer (GC) remains unclear. In this study, we investigated the impact of DLL4 overexpression on recurrence and survival in gastric cancer (GC) patients. Methods: DLL4 expression levels were evaluated by immunohistochemistry in tissue samples from 336 GC patients. Samples were classified into high and low DLL4 expression according to a cut-off of 50% positively stained cells. The correlation between DLL4 expression and clinicopathological parameters, disease-free survival (DFS), and overall survival (OS) were statistically ana
SUBMITTER: Kim Y
PROVIDER: S-EPMC6603391 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA